References
- Boado RJ, Zhang Y, Zhang Y, Pardridge WM. (2007a). Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng, 96: 381–391.
- Boado RJ, Zhang Y, Zhang Y, Pardridge WM. (2007b). Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng, 97: 1376–1386.
- Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. (2008). Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng, 99: 475–484.
- Bosslet K, Czech J, Hoffmann D. (1994). Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res, 54: 2151–2159.
- de Graaf M, Boven E, Oosterhoff D, van der Meulen-Muileman IH, Huls GA, Gerritsen WR, Haisma HJ, Pinedo HM. (2002). A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer, 86: 811–818.
- Duffy KR, Pardridge WM, Rosenfeld RG. (1988). Human blood-brain barrier insulin-like growth factor receptor. Metab Clin Exp, 37: 136–140.
- Gehrmann MC, Opper M, Sedlacek HH, Bosslet K, Czech J. (1994). Biochemical properties of recombinant human beta-glucuronidase synthesized in baby hamster kidney cells. Biochem J, 301 (Pt 3): 821–828.
- Haisma HJ, Sernee MF, Hooijberg E, Brakenhoff RH, vd Meulen-Muileman IH, Pinedo HM, Boven E. (1998). Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood, 92: 184–190.
- LeBowitz JH, Grubb JH, Maga JA, Schmiel DH, Vogler C, Sly WS. (2004). Glycosylation-independent targeting en-hances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci USA, 101: 3083–3088.
- Pan W, Kastin AJ. (2000). Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology, 72: 171–178.
- Pardridge WM. (2008). Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem, 19: 1327–1338.
- Sands MS, Vogler C, Kyle JW, Grubb JH, Levy B, Galvin N, Sly WS, Birkenmeier EH. (1994). Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest, 93: 2324–2331.
- Zhang Y, Wang Y, Boado RJ, Pardridge WM. (2008). Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res, 25: 400–406.